• 대한치과의사협회지
• /
• 제52권3호
• /
• pp.153-163
• /
• 2014

3-dimensional information for anatomic stucture plays a role as integral part in clinical aspect of dental practice. CBCT(cone beam computed tomography) has been accepted as useful diagnostic tool offering Volume data and images for evaluating teeth and jaws in lower radiation dose than conventional CT. CBCT equipment is essential for the quality assurance of it to ensure continued satisfactory performance and result of adequate images. Dental practitioner and oral and maxillofacial radiologist should have a responsibility and critical thinking to deliver this technology to patients in a responsible way, so that diaganostic value is maximised and radiation doses kept as low as resonably achievable. CBCT imaging modality should be used only after a review of the patient's health and imaging history and the completion of a thorough clinical examination. Clinical guidelines are systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances Dental practitioners should prescribe CBCT imaging only when they expect that the diagnostic yield will benefit patient care, enhance patient safety or improve clinical outcomes significantly. Knowledge of patient dose is essential for clinicians who are making the decision regarding the justification of the exposure. There are some limitation in the measurement of patient dose in CBCT for the approval and adaptation of conventinal methodolgy in CT. It is also important to ensure that doses are optimised and in line with any national and international guidelines. The higher radiation doses of CBCT compared with conventional radiography, mean that high standards must be maintained. The Quality Assurance(QA) programme should entail surveys and checks that are performed according to a regular timetable. QA programme should be maintained by staff to ensure adherence to the programme and to raise its importance among staff.

• 한국의학물리학회지:의학물리
• /
• 제29권2호
• /
• pp.59-65
• /
• 2018

This paper describes the clinical use of the dose verification of multileaf collimator (MLC)-based CyberKnife plans by combining the Octavius 1000SRS detector and water-equivalent RW3 slab phantom. The slab phantom consists of 14 plates, each with a thickness of 10 mm. One plate was modified to support tracking by inserting 14 custom-made fiducials on surface holes positioned at the outer region of $10{\times}10cm^2$. The fiducial-inserted plate was placed on the 1000SRS detector and three plates were additionally stacked up to build the reference depth. Below the detector, 10 plates were placed to avoid longer delivery times caused by proximity detection program alerts. The cross-calibration factor prior to phantom delivery was obtained by performing with 200 monitor units (MU) on the field size of $95{\times}92.5mm^2$. After irradiation, the measured dose distribution of the coronal plane was compared with the dose distribution calculated by the MultiPlan treatment planning system. The results were assessed by comparing the absolute dose at the center point of 1000SRS and the 3-D Gamma (${\gamma}$) index using 220 patient-specific quality assurance (QA). The discrepancy between measured and calculated doses at the center point of 1000SRS detector ranged from -3.9% to 8.2%. In the dosimetric comparison using 3-D ${\gamma}$-function (3%/3 mm criteria), the mean passing rates with ${\gamma}$-parameter ${\leq}1$ were $97.4%{\pm}2.4%$. The combination of the 1000SRS detector and RW3 slab phantom can be utilized for dosimetry validation of patient-specific QA in the CyberKnife MLC system, which made it possible to measure absolute dose distributions regardless of tracking mode.

• 대한방사선기술학회지:방사선기술과학
• /
• 제41권1호
• /
• pp.39-45
• /
• 2018

The purpose of this study is to evaluate the usefulness of a software-based quality assurance system based on Volumetric Modulated Arc Therapy treatment plan. Evaluate treatment plan through the D VH analysis, PTV mean dose ($D_{mean}$) and PTV 95% dose($D_{95}$) compare the MFX based on original treatment plan, Average error rate was $0.9{\pm}0.6%$, $1.0{\pm}0.8%$, respectively. Measuring point dose using phantom and ion chamber, the average error rate between the ionization chamber and MFX was $0.9{\pm}0.7%$, $1.1{\pm}0.7%$ (high dose region), $1.1{\pm}0.9%$, $1.2{\pm}0.7%$ (low dose region). The average gamma though of MFX and $Delta^{4PT}$ is $98.7{\pm}1.2%$, $98.4{\pm}.3%$, respectively. Through this study, A software based QA system that simplifies hardware based QA procedures that involve a lot of time and effort. It can be used as a simple and useful tool in clinical practice.

• 한국의학물리학회지:의학물리
• /
• 제30권4호
• /
• pp.120-127
• /
• 2019

Purpose: This study was designed to evaluate the dosimetric performance of Mobius3D by comparison with an aSi-based electronic portal imaging device (EPID) and Octavius 4D, which are conventionally used for patient-specific prescription dose verification. Methods: The study was conducted using nine patients who were treated by volumetric modulated arc therapy. To evaluate the feasibility of Mobius3D for prescription dose verification, we compared the QA results of Mobius3D to an aSi-based EPID and the Octavius 4D dose verification methods. The first was the comparison of the Mobius3D verification phantom dose, and the second was to gamma index analysis. Results: The percentage differences between the calculated point dose and measurements from a PTW31010 ion chamber were 1.6%±1.3%, 2.0%±0.8%, and 1.2%±1.2%, using collapsed cone convolution, an analytical anisotropic algorithm, and the AcurosXB algorithm respectively. The average difference was found to be 1.6%±0.3%. Additionally, in the case of using the PTW31014 ion chamber, the corresponding results were 2.0%±1.4%, 2.4%±2.1%, and 1.6%±2.5%, showing an average agreement within 2.0%±0.3%. Considering all the criteria, the Mobius3D result showed that the percentage dose difference from the EPID was within 0.46%±0.34% on average, and the percentage dose difference from Octavius 4D was within 3.14%±2.85% on average. Conclusions: We conclude that Mobius3D can be used interchangeably with phantom-based dosimetry systems, which are commonly used as patient-specific prescription dose verification tools, especially under the conditions of 3%/3 mm and 95% pass rate.

• 대한방사선기술학회지:방사선기술과학
• /
• 제46권3호
• /
• pp.231-238
• /
• 2023

This study aimed to compare the results of delivery quality assurance (DQA) using MapCHECK and OCTAVIUS for radiation therapy. Thirty patients who passed the DQA results were retrospectively included in this study. The point dose difference (DD) and gamma passing rate (GPR) were analyzed to evaluate the agreement between the measured and planned data for all cases, Plan complexity was evaluated to analyze dosimetric accuracy by quantifying the degree of modulation according to each plan. We analyzed the monitor units (MUs) and total MUs for each plan to evaluate the correlation between the MUs and plan complexity. We used a paired t-test to compare the DD and GPRs that were obtained using the two devices. The DDs and GPRs were within the tolerance range for all cases. The average GPRs difference between the two devices was statistically significant for the brain, and head and neck for gamma criteria of 3%/3 mm and 2%/2 mm. There was no significant correlation between the modulation index and total MUs for any of the cases. These DQA devices can be used interchangeably for routine patient-specific QA in radiation therapy.

• 한국의학물리학회지:의학물리
• /
• 제29권1호
• /
• pp.8-15
• /
• 2018

This work reports the acceptance testing and commissioning experience of the Robotic Intensity-Modulated Radiation Therapy (IMRT) M6 system with a newly released $InCise^{TM}2$ Multileaf Collimator (MLC) installed at the Yonsei Cancer Center. Acceptance testing included a mechanical interdigitation test, leaf positional accuracy, leakage check, and End-to-End (E2E) tests. Beam data measurements included tissue-phantom ratios (TPRs), off-center ratios (OCRs), output factors collected at 11 field sizes (the smallest field size was $7.6mm{\times}7.7mm$ and largest field size was $115.0mm{\times}100.1mm$ at 800 mm source-to-axis distance), and open beam profiles. The beam model was verified by checking patient-specific quality assurance (QA) in four fiducial-inserted phantoms, using 10 intracranial and extracranial patient plans. All measurements for acceptance testing satisfied manufacturing specifications. Mean leaf position offsets using the Garden Fence test were found to be $0.01{\pm}0.06mm$ and $0.07{\pm}0.05mm$ for X1 and X2 leaf banks, respectively. Maximum and average leaf leakages were 0.20% and 0.18%, respectively. E2E tests for five tracking modes showed 0.26 mm (6D Skull), 0.3 mm (Fiducial), 0.26 mm (Xsight Spine), 0.62 mm (Xsight Lung), and 0.6 mm (Synchrony). TPRs, OCRs, output factors, and open beams measured under various conditions agreed with composite data provided from the manufacturer to within 2%. Patient-specific QA results were evaluated in two ways. Point dose measurements with an ion chamber were all within the 5% absolute-dose agreement, and relative-dose measurements using an array ion chamber detector all satisfied the 3%/3 mm gamma criterion for more than 90% of the measurement points. The Robotic IMRT M6 system equipped with the $InCise^{TM}2$ MLC was proven to be accurate and reliable.

• 한국의학물리학회:학술대회논문집
• /
• 한국의학물리학회 2006년도 제33회 추계학술대회 발표논문집
• /
• pp.58-58
• /
• 2006

• 대한방사선치료학회지
• /
• 제32권
• /
• pp.93-109
• /
• 2020

목 적: 나선형 토모테라피 방사선치료를 위한 환자별 품질관리용 라디오크로믹 필름 및 3차원 분석시스템인 Dosimetry CheckTM (DC, MathResolutions, USA)의 성능평가를 시행하였다. 대상 및 방법: 인체모형팬톰(Anderson Rando Phantom, USA)을 이용하여 위치 변이가 있는 3가지 형태의 복부 종양(130.6㎤), 복막 후면 종양(849.0㎤) 및 전 복부 전이 종양(3131.0㎤)을 모델링하였다. 조사면 고정너비(field width, FW)를 2.5-cm, 5.0-cm, 피치(pitch) 0.287, 0.43으로 하여 부위별 4개씩(plan01-plan04), 총 12개의 비교용 치료계획을 수립하였다. 이온전리함(1D)과 라디오크로믹 필름(Gafchromic EBT3, Ashland Advanced Materials, USA)을 치즈팬톰 내 삽입하는 방법(2D)과 빔 플루언스 로그정보를 이용하여 CT영상 위에 선량을 3차원으로 재구성하는 방식의 DC측정을 진행하였다. 스레드효과(thread effect)를 분석을 위해 리플(ripple) 진폭(%)를 계산하였고, 선량 분포의 패턴 분석을 위해 감마인덱스 분석(DD: 3%/DTA: 3mm, 합격 문턱 값: 95%)을 수행하였다. 결 과: 리플 진폭 측정 결과 복막 후면 종양이 평균 23.1%로 가장 높았다. 라디오크로믹 필름의 분석결과, 절대 선량 평균 1.0±0.9%, 감마인덱스분석 평균 96.4±2.2%로 95% 이상 통과하였으나 전 복부 전이 종양과 같이 넓은 부위 평가에 범위의 제한적이었다. 인체모형팬톰에 적용한 DC 분석결과 FW가 5.0-cm인 세 부위의 2D 및 3D 플랜 평균이 91.8±6.4%였다. 세 단면 및 선량 프로파일 분석을 통해 복막 후면 및 전 복부 종양 표적 전체 영역에 분석이 가능하였고, 선량-용적 히스토그램을 통한 계획 선량 대 측정의 선량 오차가 FW 및 pitch에 따라 커지는 것을 확인하였다. 결 론: DC측정방법은 별도의 측정기 없이 조사 중 측정된 빔 플루언스 로그정보만으로 3차원 환자 영상 데이터 위에 선량 오류를 구현할 수 있고 종양의 위치나 크기에 제한이 없어 크고 불규칙한 종양의 나선형 토모테라피의 치료 시 환자별 품질관리 성능이 매우 우수하며 활용도가 높을 것으로 생각한다.

• 한국의학물리학회지:의학물리
• /
• 제19권1호
• /
• pp.35-41
• /
• 2008

양성자치료는 양성자의 물리적 특성으로 인해 인체 내의 특정범위에 모든 에너지를 전달하고 감쇠되어 타겟조직 뒤에 존재하는 정상조직에는 방사선이 조사되지 않는 큰 장점을 가진 치료법이다. 이 방법은 인체 내의 암 조직을 타겟으로 했을 때, 빔 방향에서의 타겟의 2차원적인 모양은 황동으로 제작된 블럭을 통해 정상조직에 들어가는 방사선을 차폐하고 마진을 주어서 GTV (eross Tumor Volume)에 90% 이상의 선량이 전달되도록 조절한다. 그리고, 양성자 빔의 날줄방향 (longitudinal)에서의 타겟의 3차원적인 모양을 고려하여 PMMA로 이루어진 보상체(compensator)를 밀링머신으로 조각하여 타겟에 방사선이 정확하게 분포되도록 한다. 이러한 보상체의 정확한 정도 관리를 위해 현재 사용되는 수동적인 방법을 보완하여 X선 영상으로 해당하는 보상체의 영상을 획득하여 이 영상을 기반으로 정도관리를 할 수 있는 방법을 제안하였고, 제안한 방법으로 보상체의 각각의 깎여진 평면의 모양과 두께를 정성적으로 비교 및 평가할 수 있었으며 두 영상의 차이가 80% 이상 맞는 것으로 확인되었다. 이를 바탕으로 영상을 이용한 정도관리 프로그램을 보완하여 추후 실제 양성자치료 정도관리에 사용될 예정이다.

• 한국의학물리학회지:의학물리
• /
• 제30권4호
• /
• pp.112-119
• /
• 2019

Purpose: The advantages of ocular proton therapy are that it spares the optic nerve and delivers the minimal dose to normal surrounding tissues. In this study, it developed a solid eye phantom that enabled us to perform quality assurance (QA) to verify the dose and beam range for passive single scattering proton therapy using a single phantom. For this purpose, a new solid eye phantom with a polymethyl-methacrylate (PMMA) wedge was developed using film dosimetry and an ionization chamber. Methods: The typical beam shape used for eye treatment is approximately 3 cm in diameter and the beam range is below 5 cm. Since proton therapy has a problem with beam range uncertainty due to differences in the stopping power of normal tissue, bone, air, etc, the beam range should be confirmed before treatment. A film can be placed on the slope of the phantom to evaluate the Spread-out Bragg Peak based on the water equivalent thickness value of PMMA on the film. In addition, an ionization chamber (Pin-point, PTW 31014) can be inserted into a hole in the phantom to measure the absolute dose. Results: The eye phantom was used for independent patient-specific QA. The differences in the output and beam range between the measurement and the planned treatment were less than 1.5% and 0.1 cm, respectively. Conclusions: An eye phantom was developed and the performance was successfully validated. The phantom can be employed to verify the output and beam range for ocular proton therapy.